

DAFTAR PUSTAKA

Action on Preeclampsia. (2004). Preeclampsia Community Guideline (Precog): evidence-based screening and detection of pre-eclampsia. *Action on Preeclampsia* .

Akolekar, Zaragoza, Poon, Pepes, Nicolaides. (2008). Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia. *Ultrasound Obstet Gynecol* , 732-739.

Autiero M., Lutun A., Tjwa M., Carmeliet P. (2003). Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. *J.Thromb. Haemost* , 1356-1370.

Baker PN., Cunningham FG. (2009). Platelet and coagulation abnormalities. In R. J. Lindheimer MD, *Chesley's Hypertensive Disorders* (2nd Edition ed., pp. 349 –375). Connecticut: Elsevier.

Barleon B., Sozzani S., Zhou D., Weich HA., Mantovani, Marmé D. (1996). Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. *Blood* , 3336-3343.

Bdolah Y., Karumanchi SA., Sachs BP. (2005). Recent Advances in Understanding of Preeclampsia. *Croat Med J* , 728-736.

Bellamy L., Casas JP., Hingorani AD., Williams DJ. (2007). Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and metaanalysis. *BMJ* , 974–977.

Cerdeira AS., Karumanchi SA. (2012). Angiogenic factors in preeclampsia and related disorders. *Cold Spring Harb Perspect Med* .

Chen Q, et al. (2010). The role of autocrine TGFbeta1 in endothelial cell activation induced by phagocytosis of necrotic trophoblasts: a possible role in the pathogenesis of pre-eclampsia. *J Pathol* , 87-95.

Côté, Brown, Lam, Dadelszen, Firoz, Liston. (2008). Diagnostic accuracy of urinary spot protein:creatinine ratio for proteinuria in hypertensive pregnant women: systematic review. *BMJ* .

Cunningham, FG. (2014). Hypertensive Disorders in Pregnancy. In *Williams Obstetrics, 24th eds* (pp. 1515-1516). New York: The McGraw-Hill Companies.

Cunningham, Norman, Kenneth, Larry, John, Katharine. (2005). *Williams obstetrics. 22nd ed.* New York: Williams and Wilkins.

Davison J., Homuth V., Jeyabalan A., Conrad KP., Karumanchi A., Quaggin S. (2004). New Aspects in the Pathophysiology of Preeclampsia. *J Am Soc Nephrol* , 2440-2448.

Desai, J. (1999). Signal Transduction and Biological Function of Placental Growth Factor on Primary Human Trofoblast. *J Biology of Reproduction*, 60 : 887-892

Duckitt K., Harrington D. (2005). Risk factors for preeclampsia at antenatal booking: systematic review. *BMJ* , 565.

Duley L., Meher S., Abalos E. (2006). Management of pre-eclampsia. *BMJ* , 463–468.

Eskenazi B., Fenster L., Sidney S. (1991). A multivariate analysis of risk factors for preeclampsia. *JAMA* , 237-241.

Farina, Sandie. (2013). Perbedaan Kadar Soluble Fms-like Tyrosine Kinase dan Placental Growth Factor pada Preeklamsia dan Kehamilan Normal. Universitas Sebelas Maret.

Ferrara N. (2001). Role of vascular endothelial growth factor in regulation of physiological angiogenesis. *Am J Physiol Cell Physiol* , 1358–1366.

Ferrara, N. (2007). Angiogenesis. In N. Ferrara, *Vascular Endothelial Growth Factor : Pathophysiology and Clinical Implications* (pp. 38-48). Florida: Taylor and Francis Group.

Fong GH., Rossant J., Gertsenstein M., Breitman ML. (1995). Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. *Nature* , 66-70.

Fong GH., Zhang L., Bryce DM., Peng J. (1999). Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. *Development* , 3015-3025.

Genbachev O., Zhou Y., Ludlow JW. (1997). Regulation of human placental development by oxygen tension. *Science* , 1669-1672.

Gurnadi, Mose, Handono, Satari, Anwar, Fauziah, et al. (2015). Difference of concentration of placental soluble fms-like tyrosine kinase-1(sFlt-1), placental growth factor (PIGF), and sFlt-1/PIGF ratio in severe preeclampsia and normal pregnancy. *BioMed Central* , 1-5.

He Y., Smith SK., Day KA., Clark DE., Licence DR., Charnock-Jones DS. (1999). Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. *MolEndocrino* , 537–545.

Hirashima, C., Ohkuchi, A., Arai, F., Takahashi, K., Suzuki, H., Watanabe, T., et al. (2005). Establishing reference values for both total soluble Fms-

like tyrosine kinase 1 and free placental growth factor in pregnant women. *Hypertens. Res.* , 727-732.

Huppertz., B. (2008). Placental Origins of Preeclampsia. *Hypertension*, 970-975.

Indumati V., Kodliwadmth MV., Sheela MK. (2011). The Role of serum Electrolytes in Pregnancy induced hypertension. *Journal of Clinical and Diagnostic Research* , 66-69.

Iyer, S., Leonidas, D., Swaminathan, G., Maglione, D., Battisti, M., Tucci, M., et al. (2001). The crystal structure of human placenta growth factor-1 (PlGF-1), an angiogenic protein, at 2.0 Å resolution. *J. Biol. Chem* , 12153-12161.

Kemenkes, RI. (2014). *Situasi Kesehatan Ibu*. Jakarta: Kemenkes RI.

Kendall RL., Thomas KA. (1993). Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. *Proc Natl Acad Sci U S A* , 10705–10709.

Kendall RL., Wang G., Thomas KA. (1996). Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. *Biochem. Biophys. Res. Commun* , 324-328.

Kita N., Mitsushita J. (2008). A possible placental factor for preeclampsia : placental factor for preeclampsia : sFlt-1. *Curr. Med. Chem* , 711-715.

Kumar P., Sharma JB. (2010). Hypertensive Disorders in Pregnancy. *JIMSA* , 261-266.

Lai, Larroca, Peeva, Poon, Wright, Nicolaidis. (2014). Competing risks model in screening for preeclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30–33 weeks' gestation. *Fetal Diagn Ther* , 240-248.

Lam C., Lim KH., Karumanchi A. (2005). Circulating Angiogenic Factors in the Pathogenesis and Prediction of Preeclampsia. *Hypertension* , 1077-1085.

Lehnen, Mosblech, Reineke, Puchooa, Menke-Mollers, Zechner, et al. (2013). Prenatal Clinical Assesment of sFlt-1 (Soluble fms-like Tyrosine Kinase-1)/PlGF (Placental Growth Factor) Ratio as a Diagnostic Tool for Preeclampsia, Pregnancy-induced Hypertension, and Proteinuria. *Geburtshilfe Frauenheilkd* , 440-445.

Levine RJ., Maynard SE., Qian C. (2004). Circulating angiogenic factors and the risk of preeclampsia. *N Engl J Med* (350), 672-683.

Levine, RJ., Lam, C., Qian, C. (2006). Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. *N Engl J Med* , 992-1005.

Levine, RJ., Thadhani, R., Qian, C., Lam, C., Lim, K., Yu, K., et al. (2005). Urinary placental growth factor and risk of preeclampsia. *JAMA* , 1243-1249.

Lim KH., Zhou Y., Janatpour M. (2006). Human cytotrophoblast differentiation / invasion is abnormal in pre-eclampsia. *Int J Gynaecol Obstet* , 23-27.

Lindheimer MD., Conrad KP., Karumanchi SA. (2008). Renal physiology and disease in pregnancy. In S. a. Giebisch, & H. S. Alpern RJ (Ed.), *The Kidney : Physiology and Pathophysiology* (4th Edition ed., pp. 2339 – 2398). San Diego: Elsevier.

Lindheimer MD., Taler SJ., Cunningham FG. (2008). Hypertension in pregnancy. *Journal of the American Society of Hypertension* , 484-494.

Louise, Michael, Lucilla, Rennae, Jenny, Philip, et al. (2014). Early Pregnancy Prediction of Preeclampsia in Nulliparous Women, Combining Clinical Risk and Biomarkers. *Hypertension* , 644-652.

Maglione, D., Guerriero, V., Viglietto, G., Delli-Bovi, P., Persico, M. (1991). Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. *Proc. Natl. Acad. Sci. USA* , 9267-9271.

Mattukrisna. (2011). Soluble Flt-1 and PlGF : New Markers of Early Pregnancy Loss. *Plos One* 6 (issue 3) : 1-11

Maynard, SE., Min, JY., Merchan, J., Lim, KH., Li, J., Mondal, S., et al. (2003). Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. *J. Clin. Invest* , 649-658.

McDonald, SD., Malinowski, A., Zhou, Q., Yusuf, S., Devereaux, PJ. (2008). Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. *Am Heart J* , 918–930.

McKeeman, Ardill, Caldwell, Hunter, McClure. (2004). Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. *American Journal of Obstetrics & Gynecology* , 1240–1246.

Moore, AG. (2012). Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia. *J Matern Fetal Neonatal Med* (25), 2651-2657.

Mustafa, R., Ahmed, S., Gupta, A., Venuto, RC. (2012). A Comprehensive Review of Hypertension in Pregnancy. *Journal of Pregnancy* , 1-20.

Olav L., Andrew S., Holger S. (2010). The preeclampsia biomarkers soluble fms-like tyrosine kinase-1 and placental growth factor: current knowledge, clinical implications and future application. *European Journal of Obstetrics & Gynecology and Reproductive Biology* , 122–129.

Park, J., Chen, H., Winer, J., Houck, K., Ferrara, N. (1994). Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. *J. Biol. Chem* , 25646-25654.

Prawirohardjo, S. (2011). *Ilmu Kebidanan*. Jakarta: PT. Bina Pustaka Sarwono Prawirohardjo.

Putra, R.J. (2010). *Hubungan Faktor Biologik Terhadap Kadar sFlt-1 Serum pada Wanita Hamil dengan Preeklampsia Berat*. Padang: SMF Obstetri dan Ginekologi FK Unand.

Rahmi, L., Rahmatina, B., Yusrawati. (2016). Perbedaan Rerata Kadar Soluble Fms-like Tyrosine Kinase-1 (sFlt-1) Serum pada Penderita Early Onset, Late Onset Preeklampsia Berat/Eklampsia dan Kehamilan Normal. *Jurnal Kesehatan Andalas*.

Redman, CWG., Sargent IL. (2001). The pathogenesis of Pre-eclampsia. *Gynecol Obstet Fertil* , 29, 518-522.

Roberts, JM., Cooper, DW. (2001). Pathogenesis and genetics of preeclampsia. *Lancet* , 53–56.

Roberts, JM., Gammil, HS. (2005). Preeclampsia Recent Insight. *Hypertension* (46), 1243-1249.

Roberts, JM., Hubel, CA. (2009). The Two Stage Model of Preeclampsia. *Placenta*. 30(Suppl A), S32-S37.

Saftlas, AF., Olson, DR., Franks, AL., Atrash, HK., Pokras, R.. (1990). Epidemiology of preeclampsia and eclampsia in the United States 1979-1986. *Am J Obstet Gynecol* , 460-465.

Saputra, NP. (2014). *Analisa Faktor Risiko Preeklampsia*. Padang: PPDS Obstetri dan Ginekologi FK UNAND.

Sheehan, HL., Lynch, JP. (1973). *The pathology of toxemia*. Baltimore: Wilkins and Wilkins.

Shennan, AH., Waugh, J. (2003). The measurement of blood pressure and proteinuria in pregnancy. (H. Critchly, A. MacLean, L. Poston, & J. Walker, Eds.) *Preeclampsia* , pp. 305-324.

Shibuya, M., Yamaguchi, S., Yamane, A., Ikeda, T., Tojo, A., Matsushime, H., et al. (1990). Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. *Oncogene* , 519-524.

Shibuya, M. (2006). Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis . *Angiogenesis* , 225-230.

Shore, Wang, Caudle, Torry. (1997). Vascular endothelial growth factor, placenta growth factor and their receptors in isolated human trophoblast. *Placenta* , 667-665.

Sibai, BM. (2003). Diagnosis and Management of Gestational Hypertension and Preeclampsia. *The American College of Obstetricians and Gynecologists* , 102 (1).

Stegers, EAP., Dadelszen, P., Duvekot, JJ., Pijnenborg, R. (2010). Pre-eclampsia in Seminar. 376 , 631-644.

Stepan, Herraiz, Schlembach, Verlohen, Brennecke, Chantraine, et al. (2015). Implementation of the sFlt-1/PIGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice. pp. 241-246.

Tiffany, Moore, Simas, Sybil, Crawford, Matthew, et al. (2007). Angiogenic factors for the prediction of preeclampsia in high-risk women. *AJOG* , 244.

Torry, DS. (1999). Placental Growth Factor : Potential Role in Pregnancy. *Am J of Reproductive Immunology*, 41 : 78-85

Verlohen, S., Stepan, H., Dechend, R. (2012). Angiogenic growth factors in the diagnosis and prediction of pre-eclampsia. *Clin Sci* (2), 43-52.

Verlohen, S. (2010). An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. *Am J Obstet Gynecol* , 161.

Villar, Say, Gulmezoglu, Meriardi, Betran. (2003). Eclampsia and preeclampsia: a worldwide health problem for 2000 years. In Critchley, MacLean, Poston, & Walker, *Preeclampsia*. London: RCOG Press.

Wagner, L. (2004). Diagnosis and Management of Preeclampsia. *Am Fam Physician* , 2317-2324.

Widmer, M, Villar, J., Benigni, A., Conde-Agudelo, A., Karumanchi, SA., Lindheimer, M. (2007). Mapping the theories of preeclampsia and the role of angiogenic factors. *Obstet Gynecol* (109), 168–180.

Wikstrom, AK. (2007). Biochemical and Epidemiological Studies of Early-Onset and Late-Onset Pre-Eclampsia. *Acta Universitatis Upsaliensis*. Uppsala, Swedish, 11-23.

Yang, W., Ahn, H., Hinrichs, M., Torry, R., Torry, D. (2003). Evidence of a novel isoform of placenta growth factor (PIGF-4) expressed in human trophoblast and endothelial cells. *J. Reprod. Immunol* , 53-60.

Zhou, Y., Damsky, CH., Fisher, SJ. (1997). Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? *J Clin Invest* , 2152-2164.

Zhou, Y., McMaster, M., Woo, K., Janatpour, M., Perry, J., Karpanen, T., et al. (2002). Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. *Am. J. Pathol* , 1405-1423.

